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Disseminated herpes zoster infection in
a patient with lymphoma
Abstract: Immunosuppression facilitates varicella zoster virus (VZV) reactivation in
immunocompromised patients. Atypical presentation such as disseminated disease of herpes
zoster infection has been described in immunosuppressed patients. One of the best choices of
therapy in herpes zoster infection is acyclovir, but long-term therapy may cause resistance to it. In
this report a disseminated herpes zoster infection is described in a patient with T cell lymphoma
after acyclovir/valacyclovir therapy. The infection was irresponsive to acyclovir and valacyclovir
and we were unable to control the infection because it was not possible to obtain foscarnet and the
patient died due to Staphylococcus epidermis sepsis.
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Lenfomalı bir olguda yaygın herpes zoster infeksiyonu
Özet: İmmunsupresif durumlar, bağışıklığı baskılanmış bireylerde Varicella Zoster Virus (VZV)
reaktivasyonunu kolaylaştırmaktadırlar. Herpes zoster infeksiyonunun dissemine hastalık gibi
atipik prezentasyonları özellikle bu hasta grubunda tanımlanmıştır. Herpes zoster infeksiyonunda
en iyi tedavi seçeneklerinden biri asiklovirdir ancak uzun süre tedavi asiklovire direnç gelişimine
neden olabilir. Burada T hücreli lenfoması olan bir olguda asiklovir/valasiklovir tedavi sonrası
yaygın herpes zoster infeksiyonu bildirilmiştir. Bu olguda infeksiyon asiklovir ve valasiklovire
yanıtsız olup, foscarnet bulunmadığı için viral enfeksiyon kontrol altına alınamamış ve hasta
Staphylococcus epidermidis sepsisinden kaybedilmiştir.
Anahtar Sözcükler: Asiklovir, yaygın, herpes zoster, direnç, immunsupresyon, VZV
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Varicella zoster virus (VZV) is the pathogen of varicella in childhood. It is the
primary cause of latent infection in posterior ganglions and may lead to herpes
zoster infection with reactivation in adults (1). Immunosuppression facilitates
this reactivation in immunocompromised patients such as AIDS and cancer
patients and transplant receivers. Significantly VZV infection has been reported
in lymphomas with increased prevalence. Because herpes zoster infection in an
older person suggests an underlying malignant disease, VZV infection requires
special attention in these cases (1). Herpes zoster infection is generally unilateral;
however, bilateral involvement and even disseminated infection may be seen in
these special cases. Bilateral infection is seen in 1 in 200 cases. Disseminated
infection has also been reported in immunosuppressed patients after vaccination
(2). Atypical presentation of VZV infection also has been reported in a patient
treated with monoclonal anti-CD52 antibody (3). The best choices of therapy for
herpes zoster infection are purine, pyrimidine, nucleotide, and pyrophosphate
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analogs; the best known drug among them is
acyclovir. However, long-term therapy may cause
resistance to acyclovir. Cross resistance is another
problem. Acyclovir-resistant strains are isolated also
from treatment-naive subjects and new anti-virals
are used for these cases (1,4-5).
Here we report a disseminated herpes zoster
infection in a patient with T cell lymphoma after
acyclovir and valacyclovir therapy.
Case Report
An 84-year-old man with diabetes mellitus was
admitted to hospital with neutropenic fever and he
had been diagnosed with T cell NHL (T cell
prolymphocytic lymphoma-small cell variant) in
September 2006. He was treated with 3 cycles of
CVP (cyclophosphamide-vincristine-prednisolone)
but did not respond. He had severe neutropenia and
infectious episodes. Rituximab was given for
probable autoimmune neutropenia but there was no
response. Fludarabine plus cyclophosphamide was
given and he did not respond again and he was
hospitalized 3 times due to febrile neutropenia. He
was hospitalized with neutropenic fever again in
March 2007 and at that time widespread painful
subcapsular vesicular lesions were detected. The
Tzanck smear was found to be positive and he was
diagnosed with herpes zoster infection and
parenteral acyclovir therapy was started. This
treatment was given for 4 weeks and a clinical

Figure 1. VZV skin lesions on the face, trunk, and extremities.
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improvement was observed and he was discharged
in May 2007. One month later he was admitted to
hospital with vesicular and infiltrative skin lesions
on the face, trunk, and extremities. Oral valacyclovir
was given on an outpatient basis. However, the
patient described severe itching of the lesions as well
as pain, especially in those located on the face. At
this time because of discrimination of disseminated
herpes zoster infection and/or lymphomatous skin
infiltration, skin biopsies were taken from the face
and left femoral lesions. Biopsy showed intraepidermal bullae formation and there was no
evidence of lymphoma infiltration. He was
hospitalized with poor general condition and fever
(Figures 1 and 2). He had severe anemia and
hypoalbuminemia. Supportive therapy was given
and the skin lesions were observed to be purulent.
Ampicillin-sulbactam and parenteral acyclovir+oral
famciclovir were started and foscarnet was
prescribed. However, respiratory arrest developed
and he died. Blood cultures showed methicillin
resistant Staphylococcus epidermidis.
Discussion
It is known that the frequent involvement of
nervous tissue by pressure of infiltration appears to
predispose one to contracting herpes zoster. The use
of cytotoxic immunosuppressive therapy affecting
immune response causes the activation of the
disease (1). Our patient was in the high risk group
for VZV infection due to his advanced age,

Figure 2. Necrotic and infiltrative lesions on the trunk.
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underlying lymphoproliferative disease, and
diabetes mellitus, and also due to the use of cytotoxic
chemotherapy and immunotherapy including
rituximab and anti-CD52 therapies. These factors
caused the dissemination of the disease and longterm use of acyclovir was the cause of resistant
disease in this patient. Hepatitis B virus, CMV, and
VZV reactivations have been reported related to the
use of cytotoxic chemotherapy and immunotherapy
(6,7).
Acyclovir is the standard treatment for herpes
virus infections. Acyclovir resistance is the
consequence of a mutation in the viral thymidine
kinase that abolishes enzymatic activity (TKD
mutations) in 95% of cases. Less frequently,
mutations in the viral thymidine kinase lead to the
inability to recognize acyclovir as a substrate, or
mutations in the viral DNA polymerase lead to the
inability to recognize acyclovir triphosphate. This
lastly defined mechanism also leads to cross
resistance to foscarnet. Acquired resistance to
acyclovir occurs in severely immunocompromised
patients (8).
Host immune response has a critical effect on the
severity of infection and resistance to therapy.
Primary infection or recurrences of herpetic
infection in the immunocompetent host typically
last for only a few days with rapid clearance of the
virus. Selection for resistant virus may occur only
when there is sufficient viral replication despite the
presence of anti-virals. The risk factors for resistance
are poor absorption of the drug, noncompliance,
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and the occurrence of suboptimal antiviral
concentrations (9).
The first reported case of acyclovir resistant VZV
infection occurred in a patient with lymphoma and
he was treated successfully with foscarnet (10). VZV
strains with VZV DNA polymerase gene mutations
are sensitive to bicyclic pyrimidine nucleoside
analogs while they are not sensitive to VZV strains
with viral thymidine kinase gene. Transmission of
acyclovir-resistant isolates has not been
documented, but due to the increased use of
acyclovir and newer drugs, such as famciclovir, this
transmission might occur in the future. Continued
surveillance in both immunocompetent and
immunocompromised hosts for the development of
clinical acyclovir-resistant disease is necessary (11).
In summary, acyclovir resistant strains show
cross resistance to all anti-virals dependent to
thymidine kinase. Effective drugs for viruses having
thymidine kinase gene mutation are cidofovir and
foscarnet (1). Foscarnet and cidofovir are not
available in Turkey, and therefore we were unable to
use these drugs in the early stage.
Our patient died due S. epidermidis bacteremia
secondary to disseminated VZV infection. However,
dissemination and no clinical response (probably
resistance) to acyclovir are the important points of
our case. Early recognition of resistance and the use
of effective anti-virals without cross resistance are
critically important in these immunosuppressed
patients.
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